TRK 950

Drug Profile

TRK 950

Alternative Names: TRK-950

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Toray
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Feb 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) (NCT02990481)
  • 08 Dec 2016 Toray Industries plans a first-in-human phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in USA and France (IV) (NCT02990481)
  • 29 Nov 2016 Investigation in Solid tumours in USA (IV) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top